Abstract:Objective To evaluate peripheral blood circulating CD34+ cell count in patients with myelodysplastic syndrome(MDS)-refractory anemia(RA)/refractory anemia with ring siderblasts(RARS)/refractory cytopenia with multilineage dysplasia(RCMD).Methods A total of 52 MDS-RA/RARS/RCMD patients and 19 hematopoietic stem cell donors(healthy controls) were enrolled,and their peripheral blood circulating CD34+ cell percentages and counts were determined byflow cytometry. They were classified into low risk, intermediate-Ⅰ risk,intermediate-Ⅱ risk,high risk subgroups and very low risk,low risk, intermediate risk,high risk, very high risk subgroups according to the International Prognostic Scoring System(IPSS) and World Health Organization (WHO)-Based Prognostic Scoring System(WPSS),respectively. The correlation of peripheral blood circulating CD34+ cell count with the clinical characteristics of MDS-RA/RARS/RCMD patients was analyzed.Results MDS-RA/RARS/RCMD patients had higher percentage and count of peripheral blood circulating CD34+ cells compared with healthy controls(P<0.01). There was no correlation between peripheral blood circulating CD34+ cell count inMDS-RA/RARS/RCMD patients and patients' sex,age,cytopenia degree,white blood cell count decreasing and abnormal localization of immature precursor(ALIP)(r<0.625,P>0.05),and there was correlation between peripheral blood circulating CD34+ cell count and abnormal karyotype,IPSS score, WPSS score and myelofibrosis (r>0.995,P<0.01). There were 16 MDS-RA/RARS/RCMD patients with peripheral blood circulating CD34+ cell count >10.00×106/L. Among them, there were 12 patients with complex karyotype abnormalities(10 patients with chromosome 7 abnormalities). A total of 12 and 13 patients belonged to IPSS intermediate-Ⅱ risk and WPSS high risk subgroups,respectively. There were 9 patients with myelofibrosis. Among 36 MDS-RA/RARS/RCMD patients with peripheral blood circulating CD34+ cell count <10.00×106/L,no patient had complex karyotype abnormalities or chromosome 7 abnormalities. Except for 1 patient in WPSS high risk subgroup,other patients were in IPSS low,intermediate-Ⅰ risk subgroups and WPSS very low,low and intermediate risk subgroups. Only 1 patient had myelofibrosis.Conclusions The count of peripheral blood circulating CD34+ cells increases in MDS-RA/RARS/RCMD patients,which can be further used for the classification of MDS risk.

Clinical study of the number of circulating CD34~+ cells in the peripheral blood from patients with myelodysplastic syndromes

Peripheral blood circulating CD34+ cell count in patients with MDS-RA/RARS/RCMD

Analysis of the Karyotype Abnormalities and Its Prognostic in 298 Patients with Myelodysplastic Syndrome

Expression and significance of CD34, CD117 on bone marrow mononuclear cells of patients with myelodysplastic syndrome

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

[Karyotype Analysis of 283 Cases of Myelodysplastic Syndrome].

Biological implications of circulating CD34(+) cells in myelodysplastic syndromes

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

[Evaluation of the Subsets of Lymphocytes and Their Activated Status in Patients with Myelodysplastic Syndrome].

Myelodysplastic Syndrome:A Clinical Study of 99 Cases.

Higher Level of Peripheral Blood CD34 Positive Cells Presented with Unfavorable Prognosis in Intermediate-Low Risk Acute Promyelocytic Leukemia

Association of Myeloid-Derived Suppressor Cells (mdscs) in Peripheral Blood with Characteristics in Breast Cancer Patients.

Increased Expression Of Circulating Mir-22 In The Peripheral Blood Of Patients With Myelodysplastic Syndromes Was Associated With Poorer Prognosis

Analysis of the immunophenotype features of bone marrow cells of patients with myelodysplatic syndromes

Genomic Landscape Of Cd34(+) Hematopoietic Cells In Myelodysplastic Syndrome And Gene Mutation Profiles As Prognostic Markers

[Application of Two-parameter Scoring System Based on CD105 and CD117 in MDS Diagnosis].

Clinical analysis for thirty patients with myelodysplastic syndromes

[Prospective Clinical Study of Diagnosis and Classification for 282 Cases with Primary Myelodysplastic Syndrome].

Expression and Significance of CD117 in Bone Marrow of Patients with Myelodysplastic Syndrome

Over-expression of CD200 predicts poor prognosis in MDS

Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia